Sales and Marketing Archives -

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition

Merck defends blockbuster Januvia franchise from patent challenge

https://pharmaphorum.com/news/merck-defends-blockbuster-januvia-franchise-from-patent-challenge/

News/ News/ News/ R&D/ Sales and Marketing

Revamped Novartis highlights top R&D programmes at management update

Phil Taylor iptacopan, Kisqali, Novartis, Pluvicto, R&D, remibrutinib, Sales and Marketing, Scemblix, strategy 0 Comment

With a reorganisation of Novartis now nearing completion, the Swiss pharma group is laying out its plans for

Revamped Novartis highlights top R&D programmes at management update

https://pharmaphorum.com/news/revamped-novartis-highlights-top-rd-programmes-at-management-update/

News/ News/ News/ Oncology/ Sales and Marketing

Gilead Sciences’ push into oncology is paying off, as Veklury falters

Phil Taylor Gilead Sciences, Sales and Marketing, Tecartus, Trodelvy, Veklury, Yescarta 0 Comment

Gilead Sciences’ investment in oncology has started to provide a solid return, with sales of cancer therapies breaching

Gilead Sciences’ push into oncology is paying off, as Veklury falters

https://pharmaphorum.com/news/gilead-sciences-push-into-oncology-is-paying-off-as-veklury-falters/

News/ News/ News/ R&D/ Sales and Marketing

Pfizer heading for purple patch of in-house product launches

Phil Taylor Pfizer, pipeline, R&D, Sales and Marketing 0 Comment

With record-breaking revenues and profits accruing on the back of its COVID-19 products, Pfizer is planning a big

Pfizer heading for purple patch of in-house product launches

https://pharmaphorum.com/news/pfizer-heading-for-purple-patch-of-in-house-product-launches/

News/ News/ Sales and Marketing

Bayer sells testosterone drug rights to Grünenthal for €500m

Phil Taylor Bayer, Grunenthal, Nebido, Sales and Marketing, testosterone 0 Comment

Bayer’s venerable testosterone replacement product for men with hypogonadism – Nebido – is being sold to Grünenthal as

Bayer sells testosterone drug rights to Grünenthal for €500m

https://pharmaphorum.com/news/bayer-sells-testosterone-drug-rights-to-grunenthal-for-e500m/

News/ News/ Sales and Marketing

AbbVie shielded profits from tax, says Senate panel

Phil Taylor AbbVie, Financial, Humira, Sales and Marketing, tax, US 0 Comment

A report by the Senate Finance Committee has concluded that AbbVie exploited a financial loophole introduced by former

AbbVie shielded profits from tax, says Senate panel

https://pharmaphorum.com/news/abbvie-shielded-profits-from-tax-says-senate-panel/

News/ News/ Sales and Marketing

GSK beats forecasts, thanks to COVID antibody and Shingrix sales

Phil Taylor GlaxoSmithKline, Sales and Marketing, Shingrix, xevudy 0 Comment

GlaxoSmithKline has made a promising start to 2022 with a 32% rise in group sales, albeit measured against

GSK beats forecasts, thanks to COVID antibody and Shingrix sales

https://pharmaphorum.com/news/gsk-beats-forecasts-thanks-to-covid-antibody-and-shingrix-sales/

Insights/ News/ Sales and Marketing

Novartis planning thousands of job cuts, say reports

Phil Taylor jobs, Novartis, Sales and Marketing 0 Comment

Novartis has confirmed it is planning to reduce its headcount as part of a restructuring initiative announced last

Novartis planning thousands of job cuts, say reports

https://pharmaphorum.com/news/novartis-planning-thousands-of-job-cuts-say-reports/

News/ News/ Sales and Marketing

Pfizer’s COVID boom goes on, as it eyes $22bn in Paxlovid sales this year

Phil Taylor biosimilars, Comirnaty, Eliquis, Financial, Paxlovid, Pfizer, Sales and Marketing, Vyndaqel 0 Comment

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in

Pfizer’s COVID boom goes on, as it eyes $22bn in Paxlovid sales this year

https://pharmaphorum.com/news/pfizers-covid-boom-goes-on-as-it-eyes-22bn-in-paxlovid-sales-this-year/

Trending

Sales and Marketing

Login